BCBD Medicinal S.A.

Formed in 2012, it is the first and only company in Uruguay that has a kind of non-psychoactive cannabis with its own genetics, developed, registered and internationally recognized. This genetics, whose CBD content reaches or exceeds 12% and a minimum amount of the psychoactive component, is demanded by the growing use of CBD for nutritional and medicinal purposes. Its production plan includes, in addition to non-psychoactive cannabis, 25 species of plants and 5 micro-algae that provide molecules which, individually or in combination, currently attract the interest of the main international laboratories. , At the same time, the group has set itself the objective of developing an extensive number of articles and processes with CBD as a raw material for its incorporation into foods, beverages, cosmetics, as well as products aimed at improving the welfare of humans, pets and horses. . Thanks to its research and development department, specialized in the search for genetic and production improvements, the firm today has more than 20 registered brands as well as several genetics designed to achieve different characteristics. The company is in the process of patenting, both locally and abroad, four innovations that include: a new method of combined cultivation of 25 medicinal species, including non-psychoactive cannabis; 5 types of micro-algae, which provide molecules that, combined with the CBD, give their developments and innovations unique characteristics; an integrated farming system that reduces by 95% the energy consumed by lighting and production procedures that allow the generation of plants with high CBD content. These registrations and patents abroad place Uruguay not only as a primary producer but also as an innovator at the level of the most developed countries.